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Summary
Marginal structural models were developed as a semiparametric alternative to the G-computation
formula to estimate causal effects of exposures. In practice, these models are often specified using
parametric regression models. As such, the usual conventions regarding regression model
specification apply. This paper outlines strategies for marginal structural model specification, and
considerations for the functional form of the exposure metric in the final structural model. We
propose a quasi-likelihood information criterion adapted from use in generalized estimating
equations. We evaluate the properties of our proposed information criterion using a limited
simulation study. We illustrate our approach using two empirical examples. In the first example,
we use data from a randomized breastfeeding promotion trial to estimate the effect of
breastfeeding duration on infant weight at one year. In the second example, we use data from two
prospective cohorts studies to estimate the effect of highly active antiretroviral therapy on CD4
count in an observational cohort of HIV-infected men and women. The marginal structural model
specified should reflect the scientific question being addressed, but can also assist in exploration
of other plausible and closely related questions. In marginal structural models, as in any regression
setting, correct inference depends on correct model specification. Our proposed information
criterion provides a formal method for comparing model fit for different specifications.
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After introduction around the turn of the century [1-4] marginal structural models have
diffused rapidly into the biomedical literature with numerous important applications in a
range of substantive fields [5-9]. Much has been written about the identifiability
assumptions (consistency, positivity, and exchangeability), which are necessary to yield
consistent estimates of exposure (or treatment) effects on outcomes of interest. For marginal
structural models, there are published discussions about the consistency [10-12], positivity
[13-16], and exchangeability (with respect to confounding and selection bias) [14, 15]
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assumptions, as well as discussions about the specification of models used to construct
inverse probability weights [15, 17, 18]. However, while others have considered the
specification of regression models in general (e.g. Harrell [19]) little has been written about
the choice of the functional (regression) form for the exposure of interest in the final
structural model [20, 21]. Here, we discuss specification of the final functional form of the
marginal structural model, extend the use of a weighted information criterion originally
proposed for sampling-weighted data[22] to the generalized linear marginal structural
model, and illustrate some of the challenges and implications of model fitting for marginal
structural models using two examples [23, 24].
Marginal Structural Models
Marginal structural models [4] are models for the marginal expectation of a potential
outcome as a function of a specified exposure plan. We refer readers to previous literature
for a formal definition of potential outcomes [25, 26]. Let Y denote an outcome, X(t) a time
varying exposure (for simplicity, assumed binary with X(t) = 1 denoting exposure at time t,
X(t) = 0 denoting lack of exposure), and let x̅ refer to history of time varying exposure X(t)
under a specific exposure plan to the end of follow up. A marginal structural model may be
stated as g−1(E[Yx̅]) = f(x̅) where Yx̅ is the potential outcome under exposure plan x̅, g is a
link function, and f(.) is a defined function we call the exposure metric, which is typically a
linear combination of components of x̅ (e.g., cumulative exposure). Exposure plans may be
fixed or dynamic. Fixed (or static) exposure plans are knowable at study entry, and therefore
do not depend on the evolution of participant characteristics. Examples of fixed exposure
plans include: always treat (i.e., x̅ = {1,…,1}), never treat (i.e., x ̅ = {0,…,0}), treat every
other visit (i.e., x̅ = {0,1,0,1,…,0}), or initiate treatment after four visits (i.e., x ̅ = {0,0,0,0,1,
…,1}). Dynamic exposure plans are those in which the designed exposure plan depends on
time varying covariates measured after baseline [27], and are not considered further here;
see Hernán [28] or Cain [29] for examples of dynamic regimes and methods for estimating
parameters for models for dynamic exposure plans using inverse probability weighting.
The parameters of a marginal structural model are typically estimated using inverse
probability weights. One first fits a model for the probability of exposure X(t) conditional on
exposure and confounder histories. This model for the probability of exposure is then used
to compute weights equal to the inverse probability of observed exposure given exposure
and confounder histories [4, 15]. These weights deal with confounding, and can be easily
extended to handle censoring due to drop-out [30, 31]; in short, we typically view such
censoring as another exposure and only want to make inference under the plan “never drop
out”. Methods for constructing the weights have been considered elsewhere [15, 17, 32].
The weights are then applied to the observed data, and an unadjusted model for the outcome
as a function of exposure is then fit to the weighted sample. If the functional forms of the
exposure model and final structural model (i.e., the exposure metric) are correctly specified
and the identifiability assumptions of the marginal structural model (mentioned above) are
met, then the resulting estimate has a causal interpretation as the effect of exposure on the
outcome of interest. Specifically, under assumptions the weighted model for an exposure-
specific contrast in the observed outcomes corresponds to a model for an exposure-specific
contrast in the potential outcomes.
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A well-specified scientific question should imply a specific form for the exposure metric
f(.). For example, in the presence of an induction period one may wish to ignore recent
treatment when constructing the exposure metric. Alternatively, when the exposure acts
rapidly without sustained effects one may wish to ignore historic exposure when
constructing the exposure metric. Different choices of the exposure metric f(.) therefore
imply refinements in the scientific question and interpretation of the relationship between
the exposure and outcome. We are concerned here with the selection of f(.) in a marginal
structural model.
In practice, the exposure metric f(.) is often a simple function such as cumulative exposure
to visit j: that is, . However, much more general exposure metrics are possible.
For example, one might weight the cumulative exposure as , where mk are
time-specific weights; when mk = 1 for all k, f(.) simplifies to the cumulative exposure. An
example of a non-trivial mk might define the weights as a function of k, for example, mk =
1/(j − k + 1), so that the most recent exposure k = j gets weight of unity and exposure
measurements get monotonically decreasing weights as they move back in time from visit j.
More generally, an exposure metric that allows for a defined exposure window, as well as
within-window weighting, could be defined as follows:
where b≥0 is the end of the exposure window (i.e., lag), a≤b is the start of the exposure
window, and a-b+1 is the length of the exposure window. When b=j (i.e., no lag) and a=0
this within-window weighted cumulative exposure reduces to the simple weighted
cumulative exposure above. The choice of the weight function for a particular application
should be guided by expert knowledge of the substantive matter and the scientific question
under study.
When f(.) is not pre-determined by the scientific question at hand, or when the substantive
issues at hand imply several possible functions for the exposure metric, it may be desirable
to allow the observed data to influence the choice of f(.) (although such post hoc modeling
necessarily compromises interpretations of formal statistical hypothesis tests). Comparisons
of relative goodness of model fit often rely on graphical depictions of the data and
information criteria such as Akaike's (AIC) [33], defined as −2logL + 2p, where L is the
likelihood for a model and p is the number of parameters in the model (note that AIC and
other criteria do not require nested models).
Such an approach can be extended naturally to the marginal structural model setting to
compare different forms of the structural model assuming fixed weights. That is, the only
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component that varies between models is the exposure metric in the final structural model.
Then, because marginal structural models are fit using a weighted estimating equation, the
likelihood in the AIC must be replaced with a weighted likelihood [22] or quasi-likelihood
[34], depending on the functional form of the model. For a generalized linear marginal
structural model the weighted information criterion AICw is defined as QICw = −2Q̂w + 2p,
where p is the number of parameters estimated in the model and Q̂w is the weighted quasi-
likelihood component (the derivative of which with respect to the parameter of interest is the
relevant component of the estimating function). In the linear case, (and therefore in our
examples) Qŵ is the weighted likelihood assuming the normal distribution evaluated at its
maximum, namely . Here, ŵij is the estimated inverse
probability weight, yij is the observed outcome, and μ̂ij is the estimated linear predictor.
Computation of the QICw is straightforward. In the linear case, QICw can be directly
computed from observed and fitted values; Q̂w is a simple sum of squares. For generalized
linear models, computation using a weighted sum of the components of the log likelihood
requires additional work, but many software packages provide these components directly.
They are also easily computed using, for example, SAS PROC IML (sample code in online
appendix A). Care must be exercised when using computed AIC's from standard modeling
packages, as statistical software packages may report unweighted AIC's, even from weighted
data.
Linking QICw and QIC in the counterfactual data
Under certain assumptions, inverse-probability methods provide an approach for mapping
functions of observed data into functions of counterfactual data that are equal in
expectation. Here we give a heuristic proof that in the linear marginal structural model, the
expectation of the inverse-probability weighted quasi-likelihood information criterion QICw
for the observed data equals the expectation of a quasi-likelihood information criterion
applied to the counterfactual data, provided the usual assumptions hold. For simplicity of
exposition, we consider the case where each subject has two regularly spaced visits during
which time treatment changes are made and measurements are recorded followed by the
assessment of the outcome.
Let X be a treatment that can be applied at any point in time, x1,x2 be a sequence of
treatments, Yx1,x2 be a counterfactual outcome corresponding to a sequence of treatments,
and S = Yx1,x2,(x1,x2) ∊ X
2 be the set of counterfactual outcomes corresponding to all
possible treatment sequences. Let X(t) denote the observed treatment at time t, L ̅(t) denote
the history of all covariates up to time t, and let V ⊂ L(1) be some baseline covariates upon
which we wish to condition. We are interested in estimating the conditional expectation of
the counterfactual given V: E[Yx1,x2 | V] If for each subject, we observed all counterfactual
outcomes, then we could fit a model m(x1,x2,V) of E[Yx1,x2 | V] directly using regression
without the need for weighting or other control for confounding. For example, our models
above would be given by m(x1,x2,V) = β0 +β1x1 +β2x2 +V. Given a set of competing models
that have been fit to the data, m̂i, i = 1,…,I, it would be reasonable to select the optimal
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model by choosing the one with the smallest QIC (note that in the linear case the estimating
function reduces to the normal distribution log-likelihood):
where p, as before, is the number of free parameters in the model.
With only the observed data, we instead chose the model that maximizes the inverse
probability weighted quasi-likelihood information criterion:
We would like for the weighted quasi-likelihood criterion to equal our counterfactual
criterion QIC(m̂) in expectation.
To demonstrate this equality, we need to show that:
By the rule of double expectation, we can write
The only random quantity left in the inside expectation is X(2), so we re-write the inner
expectation as a sum over possible values of X(2):
Suppose that the assumption of exchangeability (i.e., no unmeasured confounders) holds
and, for simplicity, that the distribution of X(2) is known. Then given the measured
confounders, the treatment mechanism does not depend on any of the counterfactual
outcomes. Therefore the last term in the product in the denominator cancels with the
probability in the numerator.
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Again, we apply double expectation to the resulting equation:
The only random quantity left in the inside expectation is X(1), so we re-write the inner
expectation as a sum over possible values of X(1) as:
Again, assuming the distribution of X(1) is known and the exchangeability assumption
holds, P(X(1) | L̅(1)) = P(X(1) | S,L̅(1)), then we have the result that E[QICw(m̂)] =
E[QIC(m̂)]. Note that for identifiability, we require that P(X(1) = x(1) | L(1)) ≠ 0,x1 ∊ X and
P(X(2) = x(2) | X(1), L̅ (2)) ≠ 0,x2 ∊ X (i.e., experimental treatment assumption/positivity).
We note that the proof naturally extends to the generalized linear model with replacement of
(Y-m(x,v))ˆ2 by Q(y,x,v).
Simulation Study
We undertook a limited simulation study to evaluate some of the properties of our proposed
QICw measure of model fit. We generated data assuming a marginal structural model with a
continuous outcome and a binary time varying treatment with four time intervals. For each
simulation, we generated treatment X and a single covariate L at four time points as follows:
At time 1, we generated L1 from a normal distribution with mean 10 and variance 1 and a
binary treatment X1 with probability of treatment P=expit(-2.7+0.25*L0) (where
expit(x)=exp(x)/(1+exp(x)), the inverse logit. The intercept was chosen to give a baseline
exposure of 6.2%, in line with the proportion breastfed in example 1. At time i=2,3,4, Li was
generated from a normal distribution with mean Li-1+βi*Xi-1 and Xi as binary with
probability of treatment P=expit(-2.6 +0.25*Li+0.1*Xi-1). These give rise to a marginal
structural model with E[Y(x̂)] = β0 + β1X1 + β2X2 + β3X3 + β4X4.
We considered 7 scenarios, described in Table A1 in the online appendix, considering a
range of effect sizes and of model complexity. We then fit three models: the “full” or
“saturated” model fit binary indicators for each treatment-time, the “null” model fit a model
with no parameters, and the “reduced” model fit binary indicators for treatment at times 1
and 2. We considered sample sizes of 100, 1000, 5000, and 10,000, and ran 1000 repetitions
per scenario. In each simulation, we correctly specified the (known) model for the inverse
probability weights. We ran a second set of simulations with the same specification but a log
link function (so that the outcome distribution is lognormal and therefore heteroskedastic).
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Tables B1 and B2 in the online appendix summarize the results of the simulation study. For
each combination, we report the percentage of simulation runs in which the QICw selected
each model, and compare this with the similar results for the adjusted R-square. The QICw
usually (but not uniformly) selected the correct model more often than did the adjusted R-
square. However, QICw tended to select models with more parameters, while the adjusted R-
square tended to select models with fewer parameters. Results for the lognormal model
(Table B2) were similar; however the QIC performed worse with increasing sample size,
likely due to misspecification of the variance.
Example One: Breastfeeding and infant weight gain
The PROBIT study used a cluster randomized breastfeeding promotion intervention, and
followed 17,044 infants for weight gain over the first year of life [35], as well as infection
[36] and long-term outcomes which are not considered here [37-42]. We follow Platt et al.
[43] and consider the effect of breastfeeding during the first year of life on infant weight at
12 months.
We fit marginal structural linear models with four choices for the exposure metric. In all
models we use (the same) minimally stabilized weights (i.e., the numerator for all weights is
the marginal probability of observed exposure at that time) to focus on the marginal
estimates of the effect of the exposure in the population. The first model, following Platt et
al. [43], considered indicator variables for breastfeeding in each of the time intervals
between visits, which occurred at 1, 2, 3, 6, 9, and 12 months to study the effect on weight at
12 months. In this study every mother-child pair initiates breastfeeding, breastfeeding is
assumed not to restart once stopped and data were only collected on these intervals.
Therefore, in this model the exposure specification is “saturated”; that is, each possible
exposure history completely determines the expected value of the potential outcome (infant
weight at 12 months) and the model has the maximum number of free parameters. The
second, third, and fourth exposure metrics were developed to examine simplifications
relative to the exposure-saturated model, and considered cumulative breastfeeding; that is,
weight was modeled as a linear, quadratic, and cubic function of the cumulative number of
prior months breastfed. All four models are plausible given the underlying biology of
breastfeeding and infant weight gain in the first year of life; our goal here is to compare
these four models using the modified QICw described above. A graphical depiction of
results from the saturated marginal structural models is provided in Figure 1. Summary
statistics including QICw for the four models are presented in Table 1.
The exposure-saturated model suggests the effect of breastfeeding cessation on weight at 12
months was strongest for breastfeeding cessation between 6 and 9 months and relatively
small before or thereafter. The simple linear cumulative breastfeeding model suggests that
weight is lower by 25 g per month breastfed at 12 months. The quadratic model provided
similar inferences to the linear model, except for the shortest durations, while the cubic
model fit closely resembled that of the exposure-saturated model. The QICw was lowest for
the cubic model, slightly higher for the exposure-saturated model and highest for the linear
and quadratic models. Standard errors of individual coefficients (not shown) were similar
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across the models explored. Figure B1 (online appendix) shows a plot of residuals from the
four proposed models; no patterns are apparent and all models showed similar results.
Example Two: Effect of Highly Active Antiretroviral Therapy on CD4 cell
count
Cole et al. reported on the effect of highly active antiretroviral therapy on the evolution of
CD4-positive T-lymphocyte (CD4 cell) count among human immunodeficiency virus
(HIV)-positive participants using inverse probability-of-treatment-and-censoring weighted
estimation of a marginal structural repeated measures model [23]. In summary, 60% of
1,763 eligible participants from two US cohort studies followed between 1996 and 2002
initiated highly active antiretroviral therapy. For further details about study design and
analysis please see reference [23]. As reported, the weighted estimate of the difference in
mean CD4 cell count at 1 year among participants continuously treated versus those never
treated was 71 cells/mm3 (95% confidence limits: 48, 95) with an estimated continued
increase of 29 cells/mm3 per year (estimated effect at 6 years: 216 cells/mm3). Here, to
facilitate graphical depiction of the data we again use minimally stabilized weights, which
stabilize only on the history of exposure and time, rather than additionally stabilizing on
select baseline covariates, as was done in the reported analysis. Therefore, the 1 year and per
year greater than 1 year differences in CD4 cell count due to treatment were 80 (95% CL:
45, 115) and 16 cells/mm3 per year, respectively.
Figure 2 presents the difference in CD4 cell count between exposed and unexposed groups
as well as a point-wise 95 percent point-wise confidence band in grey-shade. Our motivation
for a 2-piece linear spline is apparent in Figure 2, where the slope of the difference is
relatively steep in the first year, and then appears less steep in the second through fifth years,
with some apparent instability in the final year.
A comparison of several candidate exposure specifications is provided in Table 2. We
compared (1) an intercept-only model; (2) a model with no effect for exposure but an
intercept, a spline for follow up time and centered baseline CD4 count; (3) model 2 with a
linear effect for cumulative exposure; (4) model 2 with a curvilinear effect for cumulative
exposure; (5) model 2 with a 2-piece linear spline for cumulative exposure; and (6) an
unsmoothed model, which (akin to the exposure-saturated model in example one) allowed
the difference in CD4 cell count to vary nonparametrically at each semiannual study visit. In
the original report, based on the combination of biological knowledge [23], prior literature
[44], and the apparent inflection at one year in Figure 2, the authors presented Model 5,
including the two-piece linear spline for cumulative exposure. In Table 2, we demonstrate
that this model (5) had the lowest QICw among the models considered. However, the
curvilinear model (4) fit these data nearly as well as the 2-part linear spline model (5). Even
a simpler linear model (3) was not wholly unreasonable; this can be checked visually by
drawing a straight line through the point-wise confidence band in Figure 2. Figure B2
(online appendix) shows a plot of residuals from the six proposed models; all models
showed similar results and no patterns are apparent.
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In most regression modeling settings, appropriate specification of the functional form of the
regression model is essential to valid inference [45]. These standard considerations apply to
model selection in marginal structural models. To date, most implementations of marginal
structural models have used simple forms of the exposure (e.g., always vs. never exposed,
cumulative exposure) for the final structural regression model and have not discussed model
selection. Here, we have proposed an information criterion for use in assessing model fit in
marginal structural models. To our knowledge this is the first use of such a criterion in this
context, and these statistics may play an important role in the practical usage of marginal
structural models.
In the limited simulation study, we demonstrated that our QICw performs better than does
the adjusted R-squared. When the model was fully parameterized, the QICw almost always
selected the correct model, while the adjusted R-squared usually selected a reduced model.
When a reduced model was correct, the QICw tended to select either the full or reduced
model, almost never under-specifying the model.
In the breastfeeding example, more detailed inferences were uncovered when the functional
form of exposure was explored; fully-specified models, linear models, and curvilinear
models fit the data relatively similarly but the fully-specified (exposure-saturated) model
showed important patterns that were not evident based on simpler models, providing insight
into the association between breastfeeding and growth. In the CD4 example, alternative and
simpler functional forms fit the data nearly as well as the published two-part linear model.
Altering the functional form of the regression model, including the exposure metric, may
change the scientific question being asked. Substantive expertise should drive selection of
the functional form if possible, as biological plausibility of the functional form can lend
credence to the results. However, knowledge can be gained when differing functional forms
provide different fits to the data. For instance, if models specifying different exposure
windows give substantially different fits this can inform the investigator about the critical
windows of exposure. Exposure-saturated models similar to those fit in example one may
identify thresholds or jumps in the effect. In particular, as in the breastfeeding example, the
saturated model suggests a jump between 6 and 9 months of breastfeeding that was not
evident in the linear or curvilinear models.
Our proposed QICw has important limitations. In particular, the validity of decisions based
on the QICw is dependent on correct specification of the variance and weight models. If
either of these is incorrectly specified, our QICw may not yield valid model comparisons.
Alternative approaches to model selection exist. Here in both examples, we concentrated on
a graphical depiction of a fairly flexible function form and several competing simpler
models. In addition to the graphical depictions we also compared QICw across the specified
models. Brookhart and van der Laan [20] and van der Laan and Dudoit [46] propose
approaches based on cross-validation that can simultaneously select variables for the weight
and structural models. These approaches depend on an initial specification of the weight
model that yields consistent but potentially highly variable estimates of a parameter of
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interest. Cross-validation is then used to optimize model specification. Here we concentrated
on optimizing the structural model with weights held fixed. Neugebauer et al.[21] proposed
comparisons against a highly flexible structural model, but their approach is technically
demanding. Doubly-robust methods [47] are robust to misspecification of the weight model
or the outcome model (though not both), and provide an opportunity for future research.
More work comparing these methods to our proposed QICw is warranted.
Three other points should be noted regarding specification of marginal structural models.
First, the specification of the functional form of the exposure in the final structural model
must be equally coarse as, or coarser than, the exposure specification in the weight model.
This ensures that control of confounding is as complete as possible given the observed
covariates. In both examples, we estimated exposure weights based on the exposure at each
time point; therefore the exposure in each structural model was specified equally as coarse
(in the case of the saturated model) or more coarse (in the case of the linear and curvilinear
models) than how the exposure was specified in the weight model.
Second, many previous applications of marginal structural models have made an (explicit or
implicit) observational intent-to-treat assumption. Namely, it is assumed that once exposed,
participants remain exposed for the remainder of their observed person-time. This
assumption was made in both examples presented here (in the breastfeeding study, a
converse intent-to-treat assumption was made, in which participants were assumed not to
restart once stopped). The assumption almost certainly holds in the breastfeeding study for
biological reasons [36]. In the CD4 example, this assumption holds for 86% of the person-
time [23]. This assumption simplifies the exposure model so that only a single model for
exposure onset is required, rather than separate models for onset, cessation, and resumption;
likewise, it dramatically simplifies potential exposure histories, leading to simpler
specification of this covariate as well. However, in cases where exposure is intermittent, this
assumption may increase rather than reduce net bias. In such settings one must consider the
potential tradeoff between correctly specifying a multiphase exposure process and
increasing the variance of the final estimate of association. If exposure is intermittent, then a
correctly specified exposure process may give estimates with high variance because
relatively few participants will follow each possible exposure plan; on the other hand, an
observational intent-to-treat assumption (or other simplifications that represent a coarsening
of the exposure process) may provide biased estimates of the exposure effect, but have
relatively low variance.
Finally, we restricted attention here to minimally stabilized models, so as to focus attention
on exposure specification alone, to facilitate graphical depictions of the data, and to allow
for marginal interpretations of effect estimates. In other applications of marginal structural
models, however, stabilization by baseline covariates may improve the properties of the
weights at a cost of complicating the final structural model [48, 49].
This paper presents a relatively simple approach to specification of exposure metrics in
marginal structural models; other, more complex model fitting approaches could be
considered. For instance, in both examples the outcome was a continuous measure. In such
cases, one might want to explore transformations of the outcome variable [50], though this
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may raise the issue of the re-transformation problem [51]. In cases where the outcome is a
time-to-event variable, analogously, one could consider a broad family of parametric
survival models [52] or a semiparametric accelerated failure time model [53, 54] as
alternatives to Cox proportional hazards model [55]. In cases where the outcome is a
dichotomous variable, the choice of link function (e.g., logit, log-linear, probit, identity) may
provide different inferences; in part because different contrasts are made (e.g., ratio versus
difference).
We illustrate the importance of correct specification of the structural form when fitting
marginal structural models, and a candidate approach to this process. Additional work on
structural model specification is needed, particularly with respect to simultaneous estimation
of the inverse probability weights and the final structural model. In marginal structural
models, as in any regression setting, correct inference often depends on correct model
specification.
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Online Appendix A
Here we provide a brief SAS program to estimate the QIC for the saturated linear model for
example 1.
**Assume data as follows;
**y outcome;
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predict logL out=score der;
ods output parameterestimates=parms hessian=hess;
ods select specifications fitstatistics parameterestimates;
*logL is the QIC;
*Below is code to estimate the robust variance matrix from PROC NLMIXED
* (provided automatically by PROC GENMOD with REPEATED option);
proc sort data=score; by i;
proc means data=score noprint; by i;
var der_b0 der_b1-der_b6;
output out=_out1_(keep=der_b0 der_b1-der_b6) sum=der_b0 der_b1-der_b6;
data _out1_; set; array d (*) der_b0 der_b1-der_b6; if d(1)=.then delete;
data _parms_(keep=estimate); set parms; if parameter^=“sigma”;
data _hess_(keep=b0 b1-b6); set hess; if parameter^=“sigma”;
proc iml;
use _parms_; read all into b;
use _hess_; read all into hess;
cov=inv(hess);
nse=sqrt(vecdiag(cov));
use _out1_; read all into x;
v=cov*(x`*x)*cov;
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print, “Standard Variance Matrix”,, cov;
print, “Robust Variance Matrix”,, v;
print, “Robust Standard Errors”,, rse;





Table B1 shows the results of the simulation study for the runs in which the linear marginal
structural model was correctly specified with the parameters listed.
Table B2 shows the results of the simulation study for the runs in which the linear marginal
structural model was incorrectly specified (with a lognormal model) and the parameters
listed.
Figure B1 shows the standardized Pearson residuals for the best fitting model for example 1,
with saturated model. The mean residual was -0.001, with a standard deviation of 0.989; 95
of 17,044 observations had residuals greater than |3|, while we would expect 44.9 such
outlying observations based on the standard normal distribution. No systematic patterns
were apparent.
Figure B2 shows the standardized Pearson residuals for the best fitting model, with a
piecewise linear spline. The mean residual was 0.007, with a standard deviation of 1.0013;
161 of 12,035 observations had residuals greater than |3|, while we would expect 31.3 such
outlying observations based on the standard normal distribution. No systematic patterns
were apparent.
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Results of simulation study, correctly specified model. For each combination, values
represent the percentage of runs in which each model-selection approach selected each
model.
Percentage of simulation runs each model selected
Saturated Reduced Simple
True model (β1,β2,β3,β4) Sample size QICw Adj R2 QICw Adj R2 QICw Adj R2
(0,0,0,0) 200 70.9 29.4 11.4 56.9 17.7 13.7
1,000 52.6 20.3 11.1 69.2 36.3 10.5
5,000 49.4 19.8 13.3 70.6 37.3 9.6
10,000 46.5 19.8 11.1 70.5 42.4 9.7
(1,1,1,1) 200 58.5 20.4 15.4 63.7 26.1 15.9
1,000 12.9 0 12.3 100 74.8 0
5,000 0.4 0 0.9 100 98.7 0
10,000 0 0 0 100 100 0
(2,2,2,2) 200 79.5 4.3 10 93.7 10.5 2
1,000 79.7 0 12.8 100 7.5 0
5,000 87.6 0 10.6 100 1.8 0
10,000 93.5 0 5.8 100 0.7 0
(3,3,3,3) 200 97.8 0 1.4 100 0.8 0
1,000 99.5 0 0.3 100 0.2 0
5,000 100 0 0 100 0 0
10,000 69.5 8 11.7 43.3 18.8 48.7
(1,1,0,0) 200 53.7 0 13.1 44.1 33.2 55.9
1,000 47.5 0 14.3 45.2 38.2 54.8
5,000 50.2 0 16 50.6 33.8 49.4
10,000 71.4 0.5 14.7 43.4 13.9 56.1
(2,2,0,0) 200 61.2 0 30.8 41.5 8 58.5
1,000 56.2 0 42.1 46.3 1.7 53.7
5,000 55.8 0 44 46.7 0.2 53.3
10,000 77.7 0 17.2 42.5 5.1 57.5
(3,3,0,0) 200 60.7 0 38.3 46.2 1 53.8
1,000 58.7 0 41.3 44.8 0 55.2
5,000 55.9 0 44.1 47.9 0 52.1
10,000 70.9 29.4 11.4 56.9 17.7 13.7
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Results of simulation study, mis-specified model. For each combination, values represent
the percentage of runs in which each model-selection approach selected each model.
Percentage of simulation runs each model selected
Saturated Reduced Simple
True model (β1,β2,β3,β4) Sample size QICw Adj R2 QICw Adj R2 QICw Adj R2
(0,0,0,0) 200 68.3 25.2 12.1 51.2 19.6 23.6
1,000 57.1 29.2 12.6 49.4 30.3 21.4
5,000 60.6 32.3 10.2 47.9 29.2 19.8
10,000 56.8 40.5 15 43.7 28.2 15.8
(1,1,1,1) 200 51.5 28.4 14.8 49.8 33.7 21.8
1,000 24.5 25.9 11.8 60 63.7 14.1
5,000 16 15 10 78.4 74 6.6
10,000 12.2 8.8 9.1 88.8 78.7 2.4
(2,2,2,2) 200 39.7 24.5 17.7 59.1 42.6 16.4
1,000 8.2 13.1 8 83.7 83.8 3.2
5,000 2.1 4.6 4.2 95.1 93.7 0.3
10,000 1.2 1.7 3.1 97.9 95.7 0.4
(3,3,3,3) 200 33.9 26.5 16.9 62.7 49.2 10.8
1,000 2.4 7.8 5.9 90.7 91.7 1.5
5,000 0.4 2.8 2.1 97.1 97.5 0.1
10,000 0 0.7 1.8 99.1 98.2 0.2
(1,1,0,0) 200 67.5 18.4 12.3 54.6 20.2 27
1,000 56.3 12.8 11.7 53.5 32 33.7
5,000 55.3 7.6 12.8 60.8 31.9 31.6
10,000 53.8 3.6 13.8 60.6 32.4 35.8
(2,2,0,0) 200 63.8 10.9 13.8 45.9 22.4 43.2
1,000 56.9 3.9 13.2 49.6 29.9 46.5
5,000 49.3 0.6 18.8 61.6 31.9 37.8
10,000 46.7 0.1 18.9 65.1 34.4 34.8
(3,3,0,0) 200 63.3 4.7 18.2 36.1 18.5 59.2
1,000 48 1 24.4 46 27.6 53
5,000 37.4 0 31.9 60.4 30.7 39.6
10,000 36.6 0 38 65.9 25.4 34.1
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Residuals for the four candidate models for Example 1, plotted against observation number.
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Residuals for the six candidate models for Example 2, plotted against years on study.
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Fitted mean weight at 12 months (kg) as a function of months breastfed, for exposure
saturated model with 95 percent point-wise confidence bands in grey-shade for 17,044
infants in a randomized breastfeeding promotion trial conducted in Belarus.
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Difference in CD4 count (cells/mm3) for 5519 antiretroviral therapy exposed and 6516
unexposed visits between April 1996 and April 2002 for 1,763 HIV-positive participants
from two US cohort studies, by years of follow up using under-stabilized inverse
probability-of-treatment-and-censoring weights as described in text and point-wise 95
percent confidence band in grey-shade.
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